secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASP Isotopes Inc. (ASPI)
CIK:        0001921865
Form:       8-K
Filed at:   2026-06-25T21:24:49+00:00
Accession:  0001477932-26-004020
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ASPI subsidiary Noble to merge into ENDRA Life Sciences with $50M investment; renamed Noble Africa Inc.
--------------------------------------------------------------------------------

- Merger: Noble (ASPI subsidiary) merges into ENDRA; each Noble unit converts to one share of Class A or Class B common stock.
- Noble Investment: ~$50M gross proceeds from 4.59M Class A units at $6.57/unit to institutional investors and 3.05M Class B units to ASPI.
- ASPI contributes its Renergen subsidiary to Noble for 55.5M Class B units, entitling ASPI to 10 votes per share in ENDRA.
- Closing conditions include ENDRA stockholder approval, SEC effectiveness, Nasdaq listing, OPIC consent, and ENDRA having ≥$3.8M cash.
- Expected closing by Dec 24, 2026; ASPI directors (Mann, Ryan, Ainscow, Moore) subscribe for ~$750K of Noble Class A units.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1921865/000147793226004020/0001477932-26-004020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1921865/000147793226004020/aspi_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-004020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer